<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1719</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2023-19-4-15-23</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почки</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Functional outcomes of repeat kidney resection in patients with cancer recurrence after nephron-sparing surgeries</article-title><trans-title-group xml:lang="ru"><trans-title>Функциональные результаты повторной резекции почки у больных с рецидивом рака после нефронсберегающих операций</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0649-3734</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhumabaev</surname><given-names>N. K.</given-names></name><name xml:lang="ru"><surname>Жумабаев</surname><given-names>Н. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Nurlan K. Zhumabaev </bold></p><p><italic>24 Kashirskoe Shosse, Moscow 115522, </italic></p><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p><bold>Жумабаев Нурлан Кыстаубекович</bold><italic><bold>, </bold></italic>спирант кафедры онкологии и лучевой терапии лечебного факультета ФГАОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России, отделения  онкоурологии ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России</p><p><italic>115522 Москва, Каширское шоссе, 24,</italic></p><p><italic>117997 Москва, ул. Островитянова, 1</italic></p></bio><email>nurlan_kj@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3670-0880</contrib-id><name-alternatives><name xml:lang="en"><surname>Komarov</surname><given-names>M. I.</given-names></name><name xml:lang="ru"><surname>Комаров</surname><given-names>М. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0727-2976</contrib-id><name-alternatives><name xml:lang="en"><surname>Klimov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Климов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522, </italic></p><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24,</italic></p><p><italic>117997 Москва, ул. Островитянова, 1</italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7748-9527</contrib-id><name-alternatives><name xml:lang="en"><surname>Matveev</surname><given-names>V. B.</given-names></name><name xml:lang="ru"><surname>Матвеев</surname><given-names>В. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0493-1166</contrib-id><name-alternatives><name xml:lang="en"><surname>Stilidi</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Стилиди</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115522, </italic></p><p><italic>1 Ostrovityanova St., Moscow 117997</italic></p></bio><bio xml:lang="ru"><p><italic>115522 Москва, Каширское шоссе, 24,</italic></p><p><italic>117997 Москва, ул. Островитянова, 1</italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russi</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-12-29" publication-format="electronic"><day>29</day><month>12</month><year>2023</year></pub-date><volume>19</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>15</fpage><lpage>23</lpage><history><date date-type="received" iso-8601-date="2023-09-14"><day>14</day><month>09</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-10-02"><day>02</day><month>10</month><year>2023</year></date></history><permissions><copyright-year>2023</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1719">https://oncourology.abvpress.ru/oncur/article/view/1719</self-uri><abstract xml:lang="en"><p><bold>Aim. </bold>To perform comparative analysis of functional outcomes of repeat kidney resection and radical nephrectomy in patients with local cancer recurrence after previous organ-sparing surgeries.</p><p><bold>Materials</bold><bold> </bold><bold>and</bold><bold> </bold><bold>methods.</bold><bold> </bold>Data on 64 patients who underwent surgical treatment at the Oncourology Department of the N.N. Blokhin National Medical Research Center of Oncology between 2000 and 2022 due to local kidney cancer recurrence after previous nephron-sparing surgeries were retrospectively and prospectively included in the study. Among these, 37 (57.8 %) patients underwent repeat kidney resection (treatment group) and 27 (42.2 %) patients underwent radical nephrectomy (control group). The groups were matched in demographic and clinical characteristics (<italic>р</italic><italic> </italic>&gt;0.05). Median diameter of recurrent tumor in the treatment and control groups was 2.5 and 3.0 cm, respectively (95 % confidence interval 2.0–3.0 cm; Q<sub>1</sub>–Q<sub>3</sub> 2.4–4.0 cm). This difference was statistically significant (<italic>р</italic><italic> </italic>= 0.012), but not clinically. Median follow-up duration was 35 (3–131) months (Q<sub>1</sub>–Q<sub>3</sub> 13–57 months).</p><p><bold>Results. </bold>Repeat nephron-sparing surgeries correlated with lower decrease in kidney function compared to organ-resecting surgical treatment. In the early postoperative period, decrease in calculated glomerular filtration rate per the CKD-EPI formula compared to baseline after re-resection and nephrectomy was 16 and 32 % (<italic>р</italic><italic> </italic>= 0.010); long-term, it was 8 ± 41 and 45 ± 22 % (<italic>р</italic><italic> </italic>&lt;0.001), respectively. Complication rates in the groups were similar: 21.6 and 29.6 %, respectively (<italic>р</italic><italic> </italic>= 0.563).</p><p><bold>Conclusion.</bold><bold> </bold>For local kidney cancer recurrence, repeat resection promotes preservation of kidney function without increased complication rate.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования </bold>– провести сравнительный анализ функциональных результатов повторной резекции почки и радикальной нефрэктомии у больных с местным рецидивом рака почки после ранее перенесенных органосохраняющих операций.</p><p><bold>Материалы и методы. </bold>В исследование ретроспективно и проспективно включены данные 64 больных, которым было проведено хирургическое лечение в отделении онкоурологии НМИЦ онкологии им. Н.Н. Блохина в период с 2000 по 2022 г. по поводу локального рецидива рака почки после ранее перенесенных нефронсберегающих операций. Из них 37 (57,8 %) пациентам выполнена повторная резекция почки (основная группа) и 27 (42,2 %) – радикальная нефрэктомия (контрольная группа). Группы были сопоставимы по демографическим и клиническим характеристикам (<italic>р</italic><italic> </italic>&gt;0,05). Медиана диаметра рецидивной опухоли в основной и контрольной группах составила 2,5 и 3,0 см соответственно (95 % доверительный интервал 2,0–3,0 см; Q<sub>1</sub>–Q<sub>3</sub> 2,4–4,0 см), что было статистически значимым (<italic>р </italic>= 0,012), но клинически незначимым различием. Медиана наблюдения составила 35 (3–131) мес (Q<sub>1</sub>–Q<sub>3</sub> 13–57 мес).</p><p><bold>Результаты. </bold>Повторные нефронсберегающие операции коррелировали с меньшим снижением почечной функции относительно органоуносящего хирургического лечения. В раннем послеопреционном периоде снижение расчетной скорости клубочковой фильтрации по формуле CKD-EPI от ее исходного уровня после ререзекции и нефрэктомии составило 16 и 32 % (<italic>р </italic>= 0,010), в отдаленном периоде – 8 ± 41 и 45 ± 22 % (<italic>p </italic>&lt;0,001) соответственно. Частота осложнений в группах была сопоставимой и составила 21,6 и 29,6 % соответственно (<italic>p </italic>= 0,563).</p><p><bold>Заключение. </bold>Повторная резекция при местном рецидиве рака почки способствует сохранению почечной функции без увеличения частоты осложнений.</p></trans-abstract><kwd-group xml:lang="en"><kwd>kidney cancer</kwd><kwd>recurrence</kwd><kwd>repeat kidney resection</kwd><kwd>partial nephrectomy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак почки</kwd><kwd>рецидив</kwd><kwd>повторная резекция почки</kwd><kwd>парциальная нефрэктомия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ljungberg B., Albiges L., Bensalah K. et al. EAU guidelines on renal cell carcinoma: 2020 update. Eur Urol 2020;67:913e24.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Mir M.C., Derweesh I., Porpiglia F. et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol 2017;71(4):606–17. DOI: 10.1016/j.eururo.2016.08.060</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Henderickx M.M., Baldew S.V., Marconi L. et al. Surgical margins after partial nephrectomy as prognostic factor for the risk of local recurrence in pT1 RCC: a systematic review and narrative synthesis. World J Urol 2022;40(9):2169–79. DOI: 10.1007/s00345-022-04016-0</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Veccia A., Falagario U., Martini A. et al. Upstaging to pT3a in patients undergoing partial or radical nephrectomy for cT1 renal tumors: a systematic review and meta-analysis of outcomes and predictive factors. Eur Urol Focus 2021;7(3):574–81. DOI: 10.1016/j.euf.2020.05.013</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Margulis V., McDonald M., Tamboli P. et al. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 2009;181(5):2044–51. DOI: 10.1016/j.juro.2009.01.043</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Weight C.J., Larson B.T., Fergany A.F. et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cTlb renal masses. J Urol 2010;183(4):1317–23. DOI: 10.1016/j.juro.2009.12.030</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kriegmair M.C., Bertolo R., Karakiewicz P.I. et al. Systematic review of the management of local kidney cancer relapse. Eur Urol Oncol 2018;1(6):512–23. DOI: 10.1016/j.euo.2018.06.007</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1–150.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Levey A.S., Stevens L.A. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55(4):622–7. DOI: 10.1053/j.ajkd.2010.02.337</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dindo D., Demartines N., Clavien P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240(2):205–13. DOI: 10.1097/01.sla.0000133083.54934.ae</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Liu N.W., Khurana K., Sudarshan S. et al. Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes. J Urol 2010;183(5):1719–24. DOI: 10.1016/j.juro.2010.01.010</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Shah P., Patel V.R., Kozel Z. et al. Laparoscopic completion nephrectomy for local surgical bed recurrence after partial nephrectomy: an analysis of procedural complexity and feasibility. J Endourol 2018;32(12):1114–9. DOI: 10.1089/end.2018.0384</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Autorino R., Khalifeh A., Laydner H. et al. Repeat robot-assisted partial nephrectomy (RAPN): feasibility and early outcomes. BJU Int 2013;111(5):767–72. DOI: 10.1111/j.1464-410X.2013.11800.x</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Morgan M.A., Roberts N.R., Pino L.A. et al. Percutaneous cryoablation for recurrent low grade renal cell carcinoma after failed nephron-sparing surgery. Can J Urol 2013;20(2):6933–7.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Johnson A., Sudarshan S., Liu J. et al. Feasibility and outcomes of repeat partial nephrectomy. J Urol 2008;180(1):89–93. DOI: 10.1016/j.juro.2008.03.030</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Gurram S., Friedberg N.A., Gordhan C. et al. Reoperative partial nephrectomy-does previous surgical footprint impact outcomes? J Urol 2021;206(3):539–47. DOI: 10.1097/JU.0000000000001837</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Yoshida K., Kondo T., Takagi T. et al. Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy of a solitary kidney. Int J Clin Oncol 2020;25(6):1155–62. DOI: 10.1007/s10147-020-01633-w</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Okhawere K.E., Grauer R., Zuluaga L. et al. Operative and oncological outcomes of salvage robotic radical and partial nephrectomy: a multicenter experience. J Robotic Surg 2023;17(4):1579–85. DOI: 10.1007/s11701-023-01538-6</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Guliev B.G. Robot-assisted repeat resection of recurrent kidney tumors. Onkourologiya = Cancer Urology 2023;19(1):37–45. (In Russ.). DOI: 10.17650/1726-9776-2023-19-1-37-45</mixed-citation><mixed-citation xml:lang="ru">Гулиев Б.Г. Робот-ассистированная повторная резекция рецидивных опухолей почки. Онкоурология 2023;19(1):37–45. DOI: 10.17650/1726-9776-2023-19-1-37-45</mixed-citation></citation-alternatives></ref></ref-list></back></article>
